{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:16:40Z","timestamp":1794107800327,"version":"4.8.0"},"reference-count":382,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019475","name":"Sidra Medicine","doi-asserted-by":"publisher","award":["SDR400105"],"award-info":[{"award-number":["SDR400105"]}],"id":[{"id":"10.13039\/100019475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019475","name":"Sidra Medicine","doi-asserted-by":"publisher","award":["SDR400175"],"award-info":[{"award-number":["SDR400175"]}],"id":[{"id":"10.13039\/100019475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","award":["MRC-01-18-120"],"award-info":[{"award-number":["MRC-01-18-120"]}],"id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019475","name":"Sidra Medical and Research Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019475","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells.<\/jats:p>","DOI":"10.1186\/s12967-023-04292-3","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T07:01:32Z","timestamp":1688713292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments"],"prefix":"10.1186","volume":"21","author":[{"given":"Gunjan","family":"Dagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashna","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Masoodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabah","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysaloun","family":"Merhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheema","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Dagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammira S. Al-Shabeeb","family":"Akil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzafar A.","family":"Macha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-6275","authenticated-orcid":false,"given":"Ajaz A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"4292_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116\u201329.","journal-title":"Eur J Cancer"},{"key":"4292_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ctrv.2017.01.008","volume":"54","author":"J Martin-Liberal","year":"2017","unstructured":"Martin-Liberal J, et al. The expanding role of immunotherapy. Cancer Treat Rev. 2017;54:74\u201386.","journal-title":"Cancer Treat Rev"},{"key":"4292_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","volume":"3","author":"SJ Oiseth","year":"2017","unstructured":"Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Meta Treat. 2017;3:250\u201361.","journal-title":"J Cancer Meta Treat"},{"issue":"1\u20133","key":"4292_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2009.09.067","volume":"625","author":"H Borghaei","year":"2009","unstructured":"Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009;625(1\u20133):41\u201354.","journal-title":"Eur J Pharmacol"},{"key":"4292_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","volume":"262","author":"WB Coley","year":"1991","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991;262:3\u201311.","journal-title":"Clin Orthop Relat Res"},{"issue":"7378","key":"4292_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139.","journal-title":"Nature"},{"key":"4292_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","volume":"90","author":"AJ Korman","year":"2006","unstructured":"Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297\u2013339.","journal-title":"Adv Immunol"},{"issue":"6382","key":"4292_CR8","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"4","key":"4292_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724\u201340.","journal-title":"Cell"},{"issue":"5","key":"4292_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"4","key":"4292_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"5256","key":"4292_CR12","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"7","key":"4292_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"12","key":"4292_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352.","journal-title":"Nat Immunol"},{"issue":"2","key":"4292_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/sj.gene.6364171","volume":"6","author":"Z Zhang","year":"2005","unstructured":"Zhang Z, et al. Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immun. 2005;6(2):145\u201352.","journal-title":"Genes Immun"},{"issue":"7","key":"4292_CR16","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","volume":"74","author":"JL Lines","year":"2014","unstructured":"Lines JL, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74(7):1924\u201332.","journal-title":"Cancer Res"},{"issue":"9","key":"4292_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","volume":"4","author":"WK Suh","year":"2003","unstructured":"Suh WK, et al. The B7 family member B7\u2013H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899\u2013906.","journal-title":"Nat Immunol"},{"issue":"5","key":"4292_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(5):273\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"4292_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","volume":"15","author":"I Melero","year":"2015","unstructured":"Melero I, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"4292_CR20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"4292_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"4292_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"key":"4292_CR23","doi-asserted-by":"publisher","first-page":"991433","DOI":"10.3389\/fimmu.2022.991433","volume":"13","author":"J Taylor","year":"2022","unstructured":"Taylor J, et al. Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Front Immunol. 2022;13:991433.","journal-title":"Front Immunol"},{"issue":"1","key":"4292_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","volume":"6","author":"J Raja","year":"2018","unstructured":"Raja J, et al. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018;6(1):140.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4292_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/77558","volume":"6","author":"DF Stojdl","year":"2000","unstructured":"Stojdl DF, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6(7):821\u20135.","journal-title":"Nat Med"},{"key":"4292_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","volume":"4","author":"H Rehman","year":"2016","unstructured":"Rehman H, et al. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.","journal-title":"J Immunother Cancer"},{"key":"4292_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/OV.S100072","volume":"6","author":"HM Babiker","year":"2017","unstructured":"Babiker HM, et al. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother. 2017;6:11\u20138.","journal-title":"Oncolytic Virother"},{"issue":"5","key":"4292_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","volume":"25","author":"S Doni\u0146a","year":"2015","unstructured":"Doni\u0146a S, et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25(5):421\u20136.","journal-title":"Melanoma Res"},{"issue":"2","key":"4292_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171\u20136.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"4292_CR30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292\u2013303.","journal-title":"Gene Ther"},{"issue":"6","key":"4292_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-1119.e10.","journal-title":"Cell"},{"key":"4292_CR32","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","volume":"10","author":"GD Cao","year":"2020","unstructured":"Cao GD, et al. The oncolytic virus in cancer diagnosis and treatment. Front Oncol. 2020;10:1786.","journal-title":"Front Oncol"},{"issue":"5","key":"4292_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","volume":"10","author":"J Santos Apolonio","year":"2021","unstructured":"Santos Apolonio J, et al. Oncolytic virus therapy in cancer: a current review. World J Virol. 2021;10(5):229\u201355.","journal-title":"World J Virol"},{"issue":"1","key":"4292_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56\u201371.","journal-title":"Immunol Rev"},{"key":"4292_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0065-2776(08)60778-6","volume":"49","author":"PD Greenberg","year":"1991","unstructured":"Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281\u2013355.","journal-title":"Adv Immunol"},{"issue":"1","key":"4292_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imr.12136","volume":"257","author":"M Ruella","year":"2014","unstructured":"Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev. 2014;257(1):14\u201338.","journal-title":"Immunol Rev"},{"issue":"1","key":"4292_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/imr.12126","volume":"257","author":"EJ Cheadle","year":"2014","unstructured":"Cheadle EJ, et al. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev. 2014;257(1):91\u2013106.","journal-title":"Immunol Rev"},{"issue":"1","key":"4292_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imr.12134","volume":"257","author":"C Yee","year":"2014","unstructured":"Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev. 2014;257(1):250\u201363.","journal-title":"Immunol Rev"},{"issue":"25","key":"4292_CR39","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u201380.","journal-title":"N Engl J Med"},{"issue":"15","key":"4292_CR40","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86(15):1159\u201366.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"4292_CR41","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550\u20137.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4292_CR42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","volume":"192","author":"C Yee","year":"2000","unstructured":"Yee C, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000;192(11):1637\u201344.","journal-title":"J Exp Med"},{"issue":"4","key":"4292_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00262-012-1378-2","volume":"62","author":"S Yang","year":"2013","unstructured":"Yang S, et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother. 2013;62(4):727\u201336.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"4292_CR44","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2217\/imt.14.86","volume":"6","author":"M Wang","year":"2014","unstructured":"Wang M, et al. Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 2014;6(12):1265\u201378.","journal-title":"Immunotherapy"},{"issue":"5796","key":"4292_CR45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126\u20139.","journal-title":"Science"},{"issue":"3","key":"4292_CR46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620\u20136.","journal-title":"Mol Ther"},{"issue":"3","key":"4292_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535\u201346.","journal-title":"Blood"},{"issue":"7","key":"4292_CR48","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4292_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133\u201351.","journal-title":"J Immunother"},{"issue":"5","key":"4292_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"4292_CR51","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4292_CR52","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138.","journal-title":"J Immunol"},{"issue":"6","key":"4292_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164(6):811\u201321.","journal-title":"Br J Haematol"},{"issue":"8","key":"4292_CR54","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333.","journal-title":"N Engl J Med"},{"issue":"16","key":"4292_CR55","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"7","key":"4292_CR56","first-page":"1022","volume":"7","author":"M Heiblig","year":"2015","unstructured":"Heiblig M, et al. Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors. World J Stem Cells. 2015;7(7):1022\u201338.","journal-title":"World J Stem Cells"},{"issue":"4","key":"4292_CR57","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"1","key":"4292_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Engineering CAR-T cells. Biomarker Res. 2017;5(1):22.","journal-title":"Biomarker Res"},{"issue":"3","key":"4292_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4292_CR60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam N, et al. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun. 2020;11(1):283.","journal-title":"Nat Commun"},{"issue":"10","key":"4292_CR61","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/cas.14169","volume":"110","author":"M Nakajima","year":"2019","unstructured":"Nakajima M, et al. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci. 2019;110(10):3079\u201388.","journal-title":"Cancer Sci"},{"issue":"11","key":"4292_CR62","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365.","journal-title":"Mol Ther"},{"issue":"2","key":"4292_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"4292_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","volume":"28","author":"RD Guest","year":"2005","unstructured":"Guest RD, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203\u201311.","journal-title":"J Immunother"},{"issue":"10","key":"4292_CR65","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","volume":"180","author":"SE James","year":"2008","unstructured":"James SE, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028\u201338.","journal-title":"J Immunol"},{"issue":"6","key":"4292_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22062818","volume":"22","author":"L Morales","year":"2021","unstructured":"Morales L, Paramio JM. Cell therapies in bladder cancer management. Int J Mol Sci. 2021;22(6):1.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4292_CR67","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.ymthe.2021.04.038","volume":"29","author":"J Julamanee","year":"2021","unstructured":"Julamanee J, et al. Composite CD79A\/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. Mol Ther. 2021;29(9):2677\u201390.","journal-title":"Mol Ther"},{"issue":"4","key":"4292_CR68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"12","key":"4292_CR69","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","volume":"184","author":"JS Bridgeman","year":"2010","unstructured":"Bridgeman JS, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex. J Immunol. 2010;184(12):6938\u201349.","journal-title":"J Immunol"},{"issue":"15","key":"4292_CR70","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1096\/fasebj.6.15.1464371","volume":"6","author":"G Gross","year":"1992","unstructured":"Gross G, Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. Faseb j. 1992;6(15):3370\u20138.","journal-title":"Faseb j"},{"issue":"6230","key":"4292_CR71","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62\u20138.","journal-title":"Science"},{"key":"4292_CR72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, et al. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"4292_CR73","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, et al. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139\u201349.","journal-title":"J Exp Med"},{"issue":"12","key":"4292_CR74","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1080\/21645515.2015.1075106","volume":"11","author":"R Andersen","year":"2015","unstructured":"Andersen R, et al. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. Hum Vaccin Immunother. 2015;11(12):2790\u20135.","journal-title":"Hum Vaccin Immunother"},{"issue":"24","key":"4292_CR75","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4292_CR76","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","volume":"64","author":"C Romeo","year":"1991","unstructured":"Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991;64(5):1037\u201346.","journal-title":"Cell"},{"issue":"5","key":"4292_CR77","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64(5):891\u2013901.","journal-title":"Cell"},{"issue":"6370","key":"4292_CR78","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/356607a0","volume":"356","author":"FA Harding","year":"1992","unstructured":"Harding FA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356(6370):607\u20139.","journal-title":"Nature"},{"issue":"12","key":"4292_CR79","first-page":"4472","volume":"7","author":"CH June","year":"1987","unstructured":"June CH, et al. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol. 1987;7(12):4472\u201381.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"4292_CR80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1084\/jem.177.1.165","volume":"177","author":"P Tan","year":"1993","unstructured":"Tan P, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7\/BB1. J Exp Med. 1993;177(1):165\u201373.","journal-title":"J Exp Med"},{"issue":"4","key":"4292_CR81","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai C, et al. Chimeric receptors with 4\u20131BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676\u201384.","journal-title":"Leukemia"},{"issue":"8","key":"4292_CR82","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453\u201364.","journal-title":"Mol Ther"},{"issue":"12","key":"4292_CR83","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, et al. In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas. Mol Ther. 2018;26(12):2727\u201337.","journal-title":"Mol Ther"},{"issue":"12","key":"4292_CR84","doi-asserted-by":"publisher","first-page":"e0144787","DOI":"10.1371\/journal.pone.0144787","volume":"10","author":"H Karlsson","year":"2015","unstructured":"Karlsson H, et al. Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS ONE. 2015;10(12):e0144787.","journal-title":"PLoS ONE"},{"issue":"3","key":"4292_CR85","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"8","key":"4292_CR86","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145\u201354.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"4292_CR87","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83\u201390.","journal-title":"Immunol Rev"},{"issue":"3","key":"4292_CR88","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"issue":"10254","key":"4292_CR89","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"2","key":"4292_CR90","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/bjh.17197","volume":"192","author":"P Jain","year":"2021","unstructured":"Jain P, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021;192(2):e38\u201342.","journal-title":"Br J Haematol"},{"issue":"16","key":"4292_CR91","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"4","key":"4292_CR92","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539\u201351.","journal-title":"Acta Pharm Sin B"},{"issue":"Suppl 1","key":"4292_CR93","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/jha2.338","volume":"3","author":"S Sengsayadeth","year":"2022","unstructured":"Sengsayadeth S, et al. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem. 2022;3(Suppl 1):6\u201310.","journal-title":"EJHaem"},{"issue":"8\u20139","key":"4292_CR94","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","volume":"29","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 2022;29(8\u20139):1080\u201396.","journal-title":"Cancer Gene Ther"},{"issue":"177","key":"4292_CR95","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.","journal-title":"Sci Transl Med"},{"issue":"224","key":"4292_CR96","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.","journal-title":"Sci Transl Med"},{"issue":"9967","key":"4292_CR97","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet"},{"issue":"1","key":"4292_CR98","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","volume":"104","author":"ML Davila","year":"2016","unstructured":"Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol. 2016;104(1):6\u201317.","journal-title":"Int J Hematol"},{"issue":"5","key":"4292_CR99","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","volume":"13","author":"KC Pehlivan","year":"2018","unstructured":"Pehlivan KC, Duncan BB, Lee DW. CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Curr Hematol Malig Rep. 2018;13(5):396\u2013406.","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"4292_CR100","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"key":"4292_CR101","unstructured":"FDA.gov., Package Insert-KYMRIAH."},{"key":"4292_CR102","unstructured":"U.S.FDA. Approved Cellular and Gene Therapy Products. Kymriah. 12 October 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"issue":"15","key":"4292_CR103","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-all. J Clin Oncol. 2021;39(15):1650\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4292_CR104","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood.V128.22.1227.1227","volume":"128","author":"KC Marianna Sabatino","year":"2016","unstructured":"Marianna Sabatino KC, Chiruvolu V, Better M. Production of anti-CD19 CAR T cells for ZUMA-3 and -4: phase 1\/2 multicenter studies evaluating KTE-C19 in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (R\/R all). Blood. 2016;128(22):1227.","journal-title":"Blood"},{"issue":"1","key":"4292_CR105","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11\u201322.","journal-title":"Blood"},{"issue":"10299","key":"4292_CR106","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502.","journal-title":"Lancet"},{"key":"4292_CR107","unstructured":"U.S.FDA. Approved Cellular and Gene Therapy Products. Tecartus. 12 October 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel."},{"key":"4292_CR108","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fped.2015.00080","volume":"3","author":"H Shalabi","year":"2015","unstructured":"Shalabi H, Angiolillo A, Fry TJ. Beyond CD19: opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia. Front Pediatr. 2015;3:80.","journal-title":"Front Pediatr"},{"issue":"4","key":"4292_CR109","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/sji.12331","volume":"82","author":"CL Lorentzen","year":"2015","unstructured":"Lorentzen CL, Straten PT. CD19-chimeric antigen receptor T cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. Scand J Immunol. 2015;82(4):307\u201319.","journal-title":"Scand J Immunol"},{"issue":"5","key":"4292_CR110","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/2040620714550773","volume":"5","author":"P Mewawalla","year":"2014","unstructured":"Mewawalla P, Nathan S. Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. Ther Adv Hematol. 2014;5(5):139\u201352.","journal-title":"Ther Adv Hematol"},{"key":"4292_CR111","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/asheducation-2011.1.110","volume":"2011","author":"JR Brown","year":"2011","unstructured":"Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2011;2011:110\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"25","key":"4292_CR112","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.19.03237","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2862\u201371.","journal-title":"J Clin Oncol"},{"issue":"303","key":"4292_CR113","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.","journal-title":"Sci Transl Med"},{"issue":"6","key":"4292_CR114","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"21","key":"4292_CR115","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood.V124.21.1982.1982","volume":"124","author":"DL Porter","year":"2014","unstructured":"Porter DL, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed refractory cell. Blood. 2014;124(21):1982\u20131982.","journal-title":"Blood"},{"issue":"26","key":"4292_CR116","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u201320.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4292_CR117","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"5","key":"4292_CR118","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/curroncol29050293","volume":"29","author":"Z Todorovic","year":"2022","unstructured":"Todorovic Z, et al. CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Curr Oncol. 2022;29(5):3647\u201357.","journal-title":"Curr Oncol"},{"issue":"3","key":"4292_CR119","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/phar.1900","volume":"37","author":"BR Shank","year":"2017","unstructured":"Shank BR, et al. Chimeric antigen receptor T cells in hematologic malignancies. Pharmacotherapy. 2017;37(3):334\u201345.","journal-title":"Pharmacotherapy"},{"issue":"24","key":"4292_CR120","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980\u201390.","journal-title":"Blood"},{"issue":"15_suppl","key":"4292_CR121","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.1200\/JCO.2016.34.15_suppl.7559","volume":"34","author":"SS Neelapu","year":"2016","unstructured":"Neelapu SS, et al. Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1\u20132 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). J Clin Oncol. 2016;34(15_suppl):7559\u20137559.","journal-title":"J Clin Oncol"},{"issue":"26","key":"4292_CR122","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"4292_CR123","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"15_Suppl","key":"4292_CR124","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2016.34.15_suppl.102","volume":"34","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, et al. Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells. J Clin Oncol. 2016;34(15_Suppl):102\u2013102.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4292_CR125","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112\u201321.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4292_CR126","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"7","key":"4292_CR127","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"12","key":"4292_CR128","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709\u201320.","journal-title":"Blood"},{"issue":"10","key":"4292_CR129","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25(10):2245\u201353.","journal-title":"Mol Ther"},{"key":"4292_CR130","unstructured":"U.S.FDA. Approved Cellular and Gene Therapy Products. Yescarta. 12 October 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel."},{"issue":"1","key":"4292_CR131","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285\u201395.","journal-title":"Mol Ther"},{"issue":"2","key":"4292_CR132","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"7","key":"4292_CR133","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629\u201339.","journal-title":"N Engl J Med"},{"key":"4292_CR134","unstructured":"U.S.FDA. Approved Cellular and Gene Therapy Products. Breyanzi. 12 October 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel."},{"issue":"10343","key":"4292_CR135","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308.","journal-title":"Lancet"},{"key":"4292_CR136","doi-asserted-by":"publisher","first-page":"204062072210807","DOI":"10.1177\/20406207221080738","volume":"13","author":"B Tbakhi","year":"2022","unstructured":"Tbakhi B, Reagan PM. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Ther Adv Hematol. 2022;13:20406207221080736.","journal-title":"Ther Adv Hematol"},{"key":"4292_CR137","first-page":"1","volume":"42","author":"A Kumar","year":"2022","unstructured":"Kumar A, et al. New directions for mantle cell lymphoma in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1\u201315.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4292_CR138","unstructured":"News, C.O. Tecartus Approved as First CAR T-Cell Therapy for Mantle Cell Lymphoma. 2020; Available from: https:\/\/www.clinicaloncology.com\/FDA-Watch\/Article\/07-20\/Tecartus-Approved-as-First-CAR-T-Cell-Therapy-for-Mantle-Cell-Lymphoma-\/59127."},{"key":"4292_CR139","unstructured":"FDA.gov. Package Insert\u2014TECARTUS. Available from: https:\/\/www.fda.gov\/media\/140409\/download."},{"issue":"14","key":"4292_CR140","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"4292_CR141","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"4292_CR142","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4\u20131BB domains: pilot clinical trial results. Blood. 2012;119(17):3940\u201350.","journal-title":"Blood"},{"issue":"1","key":"4292_CR143","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","volume":"36","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial. Leukemia. 2022;36(1):189\u201396.","journal-title":"Leukemia"},{"issue":"17","key":"4292_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14174082","volume":"14","author":"D Dima","year":"2022","unstructured":"Dima D, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022;14(17):1.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4292_CR145","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u20137.","journal-title":"Lancet Haematol"},{"key":"4292_CR146","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/BLCTT.S327016","volume":"12","author":"MJ Rendo","year":"2022","unstructured":"Rendo MJ, et al. CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges. Blood Lymphat Cancer. 2022;12:119\u201336.","journal-title":"Blood Lymphat Cancer"},{"key":"4292_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/sci-2020-029","volume":"8","author":"L Ding","year":"2021","unstructured":"Ding L, Hu Y, Huang H. Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Stem Cell Investig. 2021;8:1.","journal-title":"Stem Cell Investig"},{"issue":"1","key":"4292_CR148","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","volume":"2","author":"B Guo","year":"2016","unstructured":"Guo B, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother. 2016;2(1):28\u201335.","journal-title":"J Cell Immunother"},{"issue":"8","key":"4292_CR149","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048\u201360.","journal-title":"Clin Cancer Res"},{"key":"4292_CR150","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0959-8049(16)32614-4","volume":"69","author":"JG Berdeja","year":"2016","unstructured":"Berdeja JG, et al. Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed\/refractory multiple myeloma. Eur J Cancer. 2016;69:S5.","journal-title":"Eur J Cancer"},{"issue":"13","key":"4292_CR151","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688\u2013700.","journal-title":"Blood"},{"issue":"6","key":"4292_CR152","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321.","journal-title":"J Clin Invest"},{"key":"4292_CR153","unstructured":"U.S.FDA. FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma. 12 October 2022. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma#:~:text=The%20U.S.%20Food%20and%20Drug,(different%20types)%20of%20therapy."},{"key":"4292_CR154","unstructured":"U.S.FDA. Approved Cellular and Gene Therapy Products. Abecma. 13 October 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel."},{"issue":"8","key":"4292_CR155","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"4292_CR156","unstructured":"U.S.FDA. Approved Cellular and Gene Therapy Products. Carvykti. 13 October 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/carvykti."},{"issue":"10297","key":"4292_CR157","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"15","key":"4292_CR158","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","volume":"20","author":"J Chu","year":"2014","unstructured":"Chu J, et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res. 2014;20(15):3989\u20134000.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"4292_CR159","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"T Gogishvili","year":"2017","unstructured":"Gogishvili T, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood. 2017;130(26):2838\u201347.","journal-title":"Blood"},{"issue":"1","key":"4292_CR160","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-021-03162-2","volume":"114","author":"N Hosen","year":"2021","unstructured":"Hosen N, et al. Expression of activated integrin beta7 in multiple myeloma patients. Int J Hematol. 2021;114(1):3\u20137.","journal-title":"Int J Hematol"},{"issue":"485","key":"4292_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):1.","journal-title":"Sci Transl Med"},{"issue":"9","key":"4292_CR162","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama T, et al. Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18(9):1555\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"4292_CR163","first-page":"1637","volume":"7","author":"JD Malaer","year":"2017","unstructured":"Malaer JD, Mathew PA. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. Am J Cancer Res. 2017;7(8):1637\u201341.","journal-title":"Am J Cancer Res"},{"issue":"13","key":"4292_CR164","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196\u2013206.","journal-title":"N Engl J Med"},{"key":"4292_CR165","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","volume":"10","author":"JJ van der Schans","year":"2020","unstructured":"van der Schans JJ, van de Donk N, Mutis T. Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment. Front Oncol. 2020;10:1362.","journal-title":"Front Oncol"},{"issue":"2","key":"4292_CR166","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fernandez de Larrea","year":"2020","unstructured":"Fernandez de Larrea C, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1(2):146\u201354.","journal-title":"Blood Cancer Discov"},{"key":"4292_CR167","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.12659\/MSM.893791","volume":"21","author":"F Chen","year":"2015","unstructured":"Chen F, et al. Construction of anti-CD20 single-chain antibody-CD28-CD137-TCRzeta recombinant genetic modified T cells and its treatment effect on B cell lymphoma. Med Sci Monit. 2015;21:2110\u20135.","journal-title":"Med Sci Monit"},{"issue":"5","key":"4292_CR168","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4292_CR169","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","volume":"14","author":"Q Cui","year":"2021","unstructured":"Cui Q, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):82.","journal-title":"J Hematol Oncol"},{"key":"4292_CR170","doi-asserted-by":"publisher","first-page":"954235","DOI":"10.3389\/fimmu.2022.954235","volume":"13","author":"X Xiao","year":"2022","unstructured":"Xiao X, et al. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. Front Immunol. 2022;13:954235.","journal-title":"Front Immunol"},{"key":"4292_CR171","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, et al. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011.","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"4292_CR172","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194(4):690\u2013700.","journal-title":"Br J Haematol"},{"issue":"1","key":"4292_CR173","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"4292_CR174","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella M, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126(10):3814\u201326.","journal-title":"J Clin Invest"},{"issue":"3","key":"4292_CR175","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0304-3940(88)90546-0","volume":"89","author":"BR Stevens","year":"1988","unstructured":"Stevens BR, et al. Neonatal rat brain astroglial dipeptidyl peptidase II activity regulation by cations and anions. Neurosci Lett. 1988;89(3):319\u201322.","journal-title":"Neurosci Lett"},{"issue":"6","key":"4292_CR176","doi-asserted-by":"publisher","first-page":"2100285","DOI":"10.1002\/bies.202100285","volume":"44","author":"H Simsek","year":"2022","unstructured":"Simsek H, Klotzsch E. The solid tumor microenvironment\u2014breaking the barrier for T cells. BioEssays. 2022;44(6):2100285.","journal-title":"BioEssays"},{"key":"4292_CR177","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.","journal-title":"Front Immunol"},{"issue":"4","key":"4292_CR178","first-page":"1","volume":"8","author":"L Buonaguro","year":"2020","unstructured":"Buonaguro L, Tagliamonte M. Selecting target antigens for cancer vaccine development. Vaccines (Basel). 2020;8(4):1.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"4292_CR179","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13287-022-03163-w","volume":"13","author":"A Keshavarz","year":"2022","unstructured":"Keshavarz A, et al. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Res Ther. 2022;13(1):482.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"4292_CR180","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112\u201320.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"4292_CR181","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie S, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180(7):4901\u20139.","journal-title":"J Immunol"},{"issue":"275","key":"4292_CR182","doi-asserted-by":"publisher","first-page":"275ra22","DOI":"10.1126\/scitranslmed.aaa4963","volume":"7","author":"LA Johnson","year":"2015","unstructured":"Johnson LA, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015;7(275):275ra22.","journal-title":"Sci Transl Med"},{"issue":"4","key":"4292_CR183","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1053\/j.gastro.2012.06.037","volume":"143","author":"M Chmielewski","year":"2012","unstructured":"Chmielewski M, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology. 2012;143(4):1095-107.e2.","journal-title":"Gastroenterology"},{"issue":"4","key":"4292_CR184","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312.","journal-title":"Mol Ther"},{"issue":"28","key":"4292_CR185","doi-asserted-by":"publisher","first-page":"24884","DOI":"10.18632\/oncotarget.4670","volume":"6","author":"M Prapa","year":"2015","unstructured":"Prapa M, et al. A novel anti-GD2\/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget. 2015;6(28):24884\u201394.","journal-title":"Oncotarget"},{"issue":"2","key":"4292_CR186","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","volume":"23","author":"K Sch\u00f6nfeld","year":"2015","unstructured":"Sch\u00f6nfeld K, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23(2):330\u20138.","journal-title":"Mol Ther"},{"issue":"5","key":"4292_CR187","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/jnci\/djv375","volume":"108","author":"C Zhang","year":"2016","unstructured":"Zhang C, et al. ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma. JNCI J Natl Cancer Inst. 2016;108(5):375.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"10","key":"4292_CR188","doi-asserted-by":"publisher","first-page":"e109427","DOI":"10.1371\/journal.pone.0109427","volume":"9","author":"G Zuccolotto","year":"2014","unstructured":"Zuccolotto G, et al. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS ONE. 2014;9(10):e109427.","journal-title":"PLoS ONE"},{"issue":"6","key":"4292_CR189","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.7150\/ijbs.70120","volume":"18","author":"YH Yang","year":"2022","unstructured":"Yang YH, et al. CAR-T cell therapy for breast cancer: from basic research to clinical application. Int J Biol Sci. 2022;18(6):2609\u201326.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4292_CR190","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107\u201326.","journal-title":"Immunol Rev"},{"key":"4292_CR191","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","volume":"8","author":"HR Mirzaei","year":"2017","unstructured":"Mirzaei HR, et al. Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications. Front Immunol. 2017;8:1850.","journal-title":"Front Immunol"},{"key":"4292_CR192","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/978-981-10-6020-5_17","volume-title":"Translational research in breast cancer: biomarker diagnosis, targeted therapies and approaches to precision medicine","author":"J Wang","year":"2017","unstructured":"Wang J, Zhou P. New approaches in CAR-T cell immunotherapy for breast cancer. In: Song E, Hu H, editors. Translational research in breast cancer: biomarker diagnosis, targeted therapies and approaches to precision medicine. Singapore: Springer; 2017. p. 371\u201381."},{"issue":"4","key":"4292_CR193","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4103\/IJPM.IJPM_637_18","volume":"63","author":"O Oral","year":"2020","unstructured":"Oral O, et al. Associations between the expression of mucins (MUC1, MUC2, MUC5AC and MUC6) and clinicopathologic parameters of human breast carcinomas. Indian J Pathol Microbiol. 2020;63(4):551\u20138.","journal-title":"Indian J Pathol Microbiol"},{"key":"4292_CR194","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","volume":"10","author":"R Zhou","year":"2019","unstructured":"Zhou R, et al. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 2019;10:1149.","journal-title":"Front Immunol"},{"issue":"2","key":"4292_CR195","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","volume":"133","author":"J Tchou","year":"2012","unstructured":"Tchou J, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012;133(2):799\u2013804.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"4292_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18091797","volume":"18","author":"R Munisvaradass","year":"2017","unstructured":"Munisvaradass R, et al. Human CD3+ T-cells with the anti-ERBB2 chimeric antigen receptor exhibit efficient targeting and induce apoptosis in ERBB2 overexpressing breast cancer cells. Int J Mol Sci. 2017;18(9):1.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4292_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11010021","volume":"11","author":"GM Branella","year":"2021","unstructured":"Branella GM, Spencer HT. Natural receptor- and ligand-based chimeric antigen receptors: strategies using natural ligands and receptors for targeted cell killing. Cells. 2021;11(1):1.","journal-title":"Cells"},{"issue":"3","key":"4292_CR198","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00262-017-2089-5","volume":"67","author":"B-L Zuo","year":"2018","unstructured":"Zuo B-L, et al. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor. Cancer Immunol Immunother. 2018;67(3):393\u2013401.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4292_CR199","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14030503","volume":"14","author":"MPJ Perera","year":"2022","unstructured":"Perera MPJ, et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer. Cancers (Basel). 2022;14(3):1.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4292_CR200","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/15384047.2020.1739952","volume":"21","author":"S Weimin","year":"2020","unstructured":"Weimin S, et al. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biol Ther. 2020;21(6):570\u201380.","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"4292_CR201","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans RP, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016;76(14):1257\u201370.","journal-title":"Prostate"},{"issue":"6_suppl","key":"4292_CR202","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/jco.2013.31.6_suppl.72","volume":"31","author":"SF Slovin","year":"2013","unstructured":"Slovin SF, et al. Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). J Clin Oncol. 2013;31(6_suppl):72\u201372.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4292_CR203","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724\u201334.","journal-title":"Nat Med"},{"issue":"2","key":"4292_CR204","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/etm.2020.9594","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, et al. Inflammatory signals induce MUC16 expression in ovarian cancer cells via NF-\u03baB activation. Exp Ther Med. 2021;21(2):163.","journal-title":"Exp Ther Med"},{"issue":"3","key":"4292_CR205","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ygyno.2007.02.004","volume":"105","author":"L Wang","year":"2007","unstructured":"Wang L, et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol. 2007;105(3):695\u2013702.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4292_CR206","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.canlet.2006.11.025","volume":"251","author":"MP Ponnusamy","year":"2007","unstructured":"Ponnusamy MP, et al. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett. 2007;251(2):247\u201357.","journal-title":"Cancer Lett"},{"issue":"1","key":"4292_CR207","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-020-07180-x","volume":"20","author":"T Li","year":"2020","unstructured":"Li T, Wang J. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. BMC Cancer. 2020;20(1):678.","journal-title":"BMC Cancer"},{"key":"4292_CR208","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","volume":"9","author":"JP Murad","year":"2018","unstructured":"Murad JP, et al. Effective targeting of TAG72(+) peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front Immunol. 2018;9:2268.","journal-title":"Front Immunol"},{"issue":"14","key":"4292_CR209","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1158\/1078-0432.CCR-10-0192","volume":"16","author":"AA Chekmasova","year":"2010","unstructured":"Chekmasova AA, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010;16(14):3594\u2013606.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4292_CR210","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1525-1438.1995.05040269.x","volume":"5","author":"E Wrigley","year":"1995","unstructured":"Wrigley E, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5(4):269\u201374.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"4292_CR211","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CJI.0000000000000203","volume":"41","author":"GL Owens","year":"2018","unstructured":"Owens GL, et al. Preclinical assessment of CAR T-cell therapy targeting the tumor antigen 5T4 in ovarian cancer. J Immunother. 2018;41(3):130\u201340.","journal-title":"J Immunother"},{"key":"4292_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.662064","volume":"15","author":"L Maggs","year":"2021","unstructured":"Maggs L, et al. CAR T cell-based immunotherapy for the treatment of glioblastoma. Front Neurosci. 2021;15: 662064.","journal-title":"Front Neurosci"},{"key":"4292_CR213","doi-asserted-by":"publisher","first-page":"669071","DOI":"10.3389\/fonc.2021.669071","volume":"11","author":"JS Durgin","year":"2021","unstructured":"Durgin JS, et al. Case report: prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma. Front Oncol. 2021;11:669071.","journal-title":"Front Oncol"},{"issue":"399","key":"4292_CR214","first-page":"1","volume":"9","author":"DM O'Rourke","year":"2017","unstructured":"O\u2019Rourke DM, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):1.","journal-title":"Sci Transl Med"},{"key":"4292_CR215","doi-asserted-by":"publisher","first-page":"108734","DOI":"10.1016\/j.biopha.2019.108734","volume":"113","author":"M Chen","year":"2019","unstructured":"Chen M, et al. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL\/6 mice. Biomed Pharmacother. 2019;113:108734.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"4292_CR216","first-page":"4702","volume":"12","author":"J Zeng","year":"2020","unstructured":"Zeng J, et al. IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients. Am J Transl Res. 2020;12(8):4702\u201314.","journal-title":"Am J Transl Res"},{"issue":"1","key":"4292_CR217","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown CE, et al. Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018;26(1):31\u201344.","journal-title":"Mol Ther"},{"issue":"18","key":"4292_CR218","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown CE, et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062\u201372.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4292_CR219","first-page":"1549","volume":"42","author":"L Shen","year":"2019","unstructured":"Shen L, et al. The efficacy of third generation anti-HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells. Oncol Rep. 2019;42(4):1549\u201357.","journal-title":"Oncol Rep"},{"issue":"8","key":"4292_CR220","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094\u2013101.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4292_CR221","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41698-021-00233-9","volume":"5","author":"M Prapa","year":"2021","unstructured":"Prapa M, et al. GD2 CAR T cells against human glioblastoma. NPJ Precis Oncol. 2021;5(1):93.","journal-title":"NPJ Precis Oncol"},{"key":"4292_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978195","volume":"13","author":"B Ghazi","year":"2022","unstructured":"Ghazi B, et al. CAR T-cells for colorectal cancer immunotherapy: Ready to go? Front Immunol. 2022;13: 978195.","journal-title":"Front Immunol"},{"issue":"5","key":"4292_CR223","first-page":"945","volume":"9","author":"X Deng","year":"2019","unstructured":"Deng X, et al. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo. Am J Cancer Res. 2019;9(5):945\u201358.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"4292_CR224","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/2326-6066.CIR-16-0362","volume":"6","author":"MS Magee","year":"2018","unstructured":"Magee MS, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res. 2018;6(5):509\u201316.","journal-title":"Cancer Immunol Res"},{"key":"4292_CR225","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege KM, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5:22.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4292_CR226","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12010054","volume":"12","author":"SM Sureban","year":"2019","unstructured":"Sureban SM, et al. DCLK1 monoclonal antibody-based CAR-T cells as a novel treatment strategy against human colorectal cancers. Cancers (Basel). 2019;12(1):1.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4292_CR227","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther. 2017;25(5):1248\u201358.","journal-title":"Mol Ther"},{"issue":"8","key":"4292_CR228","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.21037\/jtd.2020.03.118","volume":"12","author":"S Zhong","year":"2020","unstructured":"Zhong S, et al. CAR-T cell therapy for lung cancer: a promising but challenging future. J Thorac Dis. 2020;12(8):4516\u201321.","journal-title":"J Thorac Dis"},{"issue":"1","key":"4292_CR229","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11684-019-0683-y","volume":"13","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, et al. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Front Med. 2019;13(1):57\u201368.","journal-title":"Front Med"},{"issue":"1","key":"4292_CR230","first-page":"739","volume":"17","author":"L Ye","year":"2019","unstructured":"Ye L, et al. Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo. Exp Ther Med. 2019;17(1):739\u201347.","journal-title":"Exp Ther Med"},{"issue":"1","key":"4292_CR231","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tranon.2017.10.009","volume":"11","author":"N Li","year":"2018","unstructured":"Li N, et al. Chimeric antigen receptor-modified T cells redirected to EphA2 for the immunotherapy of non-small cell lung cancer. Transl Oncol. 2018;11(1):11\u20137.","journal-title":"Transl Oncol"},{"issue":"1","key":"4292_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-000785","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, et al. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. J Immunother Cancer. 2020;8(1):1.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4292_CR233","doi-asserted-by":"publisher","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","volume":"6","author":"X Wei","year":"2017","unstructured":"Wei X, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722.","journal-title":"Oncoimmunology"},{"issue":"8","key":"4292_CR234","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","volume":"9","author":"M Liu","year":"2020","unstructured":"Liu M, et al. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020;9(8):72.","journal-title":"Oncogenesis"},{"issue":"18","key":"4292_CR235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.126345","volume":"4","author":"L Wallstabe","year":"2019","unstructured":"Wallstabe L, et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight. 2019;4(18):1.","journal-title":"JCI Insight"},{"key":"4292_CR236","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","unstructured":"Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1\u201361.","journal-title":"Adv Cancer Res"},{"issue":"7","key":"4292_CR237","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18070","volume":"18","author":"E Loveman","year":"2014","unstructured":"Loveman E, et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol Assess. 2014;18(7):1\u2013283.","journal-title":"Health Technol Assess"},{"issue":"2","key":"4292_CR238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020271","volume":"13","author":"P Rochigneux","year":"2021","unstructured":"Rochigneux P, et al. Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials. Cancers (Basel). 2021;13(2):1.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4292_CR239","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00262-016-1949-8","volume":"66","author":"C Chen","year":"2017","unstructured":"Chen C, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother. 2017;66(4):475\u201389.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4292_CR240","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra SA, et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res. 2020;8(3):309\u201320.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4292_CR241","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12964-021-00789-w","volume":"19","author":"H-B Li","year":"2021","unstructured":"Li H-B, Yang Z-H, Guo Q-Q. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Communication and Signaling. 2021;19(1):117.","journal-title":"Cell Communication and Signaling"},{"key":"4292_CR242","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","volume":"9","author":"M Akce","year":"2018","unstructured":"Akce M, et al. The potential of CAR T cell therapy in pancreatic cancer. Front Immunol. 2018;9:2166.","journal-title":"Front Immunol"},{"issue":"2","key":"4292_CR243","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du H, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7\u2013H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221-237.e8.","journal-title":"Cancer Cell"},{"issue":"6","key":"4292_CR244","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey Jr","year":"2016","unstructured":"Posey AD Jr, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44(6):1444\u201354.","journal-title":"Immunity"},{"issue":"5","key":"4292_CR245","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11050674","volume":"11","author":"LM Whilding","year":"2019","unstructured":"Whilding LM, et al. CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel). 2019;11(5):1.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4292_CR246","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","volume":"9","author":"K Feng","year":"2018","unstructured":"Feng K, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838\u201347.","journal-title":"Protein Cell"},{"issue":"12","key":"4292_CR247","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","volume":"173","author":"M Chmielewski","year":"2004","unstructured":"Chmielewski M, et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173(12):7647\u201353.","journal-title":"J Immunol"},{"issue":"17","key":"4292_CR248","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu X, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75(17):3596\u2013607.","journal-title":"Cancer Res"},{"issue":"17","key":"4292_CR249","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso HG, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75(17):3505\u201318.","journal-title":"Cancer Res"},{"issue":"6","key":"4292_CR250","doi-asserted-by":"publisher","first-page":"863","DOI":"10.4161\/onci.20592","volume":"1","author":"JD Stone","year":"2012","unstructured":"Stone JD, et al. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology. 2012;1(6):863\u201373.","journal-title":"Oncoimmunology"},{"issue":"21","key":"4292_CR251","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.130416","volume":"4","author":"Y He","year":"2019","unstructured":"He Y, et al. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019;4(21):1.","journal-title":"JCI Insight"},{"issue":"26","key":"4292_CR252","doi-asserted-by":"publisher","first-page":"15148","DOI":"10.1073\/pnas.1920662117","volume":"117","author":"P Sharma","year":"2020","unstructured":"Sharma P, et al. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci USA. 2020;117(26):15148\u201359.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4292_CR253","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","volume":"23","author":"ZL Chang","year":"2017","unstructured":"Chang ZL, Chen YY. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23(5):430\u201350.","journal-title":"Trends Mol Med"},{"issue":"6","key":"4292_CR254","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):1426-1438.e11.","journal-title":"Cell"},{"issue":"6","key":"4292_CR255","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"1","key":"4292_CR256","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"key":"4292_CR257","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2 Suppl","key":"4292_CR258","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1188\/17.CJON.S2.29-34","volume":"21","author":"L Smith","year":"2017","unstructured":"Smith L, Venella K. Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy. Clin J Oncol Nurs. 2017;21(2 Suppl):29\u201334.","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"4292_CR259","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119\u201322.","journal-title":"Cancer J"},{"issue":"4","key":"4292_CR260","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey DT, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u201cALL.\u201d Nat Rev Clin Oncol. 2018;15(4):218.","journal-title":"Nat Rev Clin Oncol"},{"key":"4292_CR261","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"15","author":"LL Riegler","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323\u201335.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"4292_CR262","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Supplement 1","key":"4292_CR263","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke FL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;130(Supplement 1):1547\u20131547.","journal-title":"Blood"},{"issue":"Supplement_1","key":"4292_CR264","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2019-126081","volume":"134","author":"M Topp","year":"2019","unstructured":"Topp M, et al. Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B cell lymphoma. Blood. 2019;134(Supplement_1):243\u2013243.","journal-title":"Blood"},{"issue":"5","key":"4292_CR265","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10(5):702\u201323.","journal-title":"Cancer Discov"},{"issue":"568","key":"4292_CR266","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.aap9777","volume":"12","author":"MC Ramello","year":"2019","unstructured":"Ramello MC, et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019;12(568):1.","journal-title":"Sci Signal"},{"issue":"6","key":"4292_CR267","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947\u201353.","journal-title":"Nat Med"},{"issue":"2","key":"4292_CR268","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno JN, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270\u201380.","journal-title":"Nat Med"},{"issue":"18","key":"4292_CR269","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"issue":"3","key":"4292_CR270","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu I, et al. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Mol Ther. 2017;25(3):580\u201392.","journal-title":"Mol Ther"},{"issue":"1","key":"4292_CR271","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12896-019-0537-3","volume":"19","author":"A Juillerat","year":"2019","unstructured":"Juillerat A, et al. Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnol. 2019;19(1):44.","journal-title":"BMC Biotechnol"},{"issue":"499","key":"4292_CR272","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann K, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. 2019;11(499):1.","journal-title":"Sci Transl Med"},{"issue":"19","key":"4292_CR273","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650\u201360.","journal-title":"Blood"},{"issue":"8","key":"4292_CR274","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371.","journal-title":"Cancer Discov"},{"issue":"3","key":"4292_CR275","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transpl. 2021;56(3):552\u201366.","journal-title":"Bone Marrow Transpl"},{"issue":"26","key":"4292_CR276","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"1","key":"4292_CR277","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"4292_CR278","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"1","key":"4292_CR279","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ajh.24594","volume":"92","author":"H Yu","year":"2017","unstructured":"Yu H, et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am J Hematol. 2017;92(1):E11-e13.","journal-title":"Am J Hematol"},{"issue":"7750","key":"4292_CR280","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112\u20136.","journal-title":"Nature"},{"issue":"12","key":"4292_CR281","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","volume":"5","author":"HJ Jackson","year":"2015","unstructured":"Jackson HJ, Brentjens RJ. Overcoming antigen escape with CAR T-cell therapy. Cancer Discov. 2015;5(12):1238\u201340.","journal-title":"Cancer Discov"},{"issue":"11","key":"4292_CR282","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2013.185","volume":"21","author":"M Hegde","year":"2013","unstructured":"Hegde M, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21(11):2087\u2013101.","journal-title":"Mol Ther"},{"issue":"6","key":"4292_CR283","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah E, et al. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498\u2013508.","journal-title":"Cancer Immunol Res"},{"key":"4292_CR284","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin H, et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics. 2018;11:127\u201337.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"4292_CR285","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan J, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood. 2020;135(5):387\u201391.","journal-title":"Blood"},{"issue":"7","key":"4292_CR286","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies\u2014BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4292_CR287","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","volume":"25","author":"EY Jen","year":"2019","unstructured":"Jen EY, et al. FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res. 2019;25(2):473\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4292_CR288","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","volume":"5","author":"M Subklewe","year":"2021","unstructured":"Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021;5(2):607\u201312.","journal-title":"Blood Adv"},{"issue":"9","key":"4292_CR289","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049\u201358.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"4292_CR290","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5(7):571\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"37","key":"4292_CR291","doi-asserted-by":"publisher","first-page":"62730","DOI":"10.18632\/oncotarget.17528","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang N, Shi H. Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget. 2017;8(37):62730\u201341.","journal-title":"Oncotarget"},{"issue":"1","key":"4292_CR292","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-020-01294-3","volume":"20","author":"AA Bhat","year":"2021","unstructured":"Bhat AA, et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Mol Cancer. 2021;20(1):2.","journal-title":"Mol Cancer"},{"issue":"9","key":"4292_CR293","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22094584","volume":"22","author":"S Nisar","year":"2021","unstructured":"Nisar S, et al. Chemokine\u2013cytokine networks in the head and neck tumor microenvironment. Int J Mol Sci. 2021;22(9):1.","journal-title":"Int J Mol Sci"},{"key":"4292_CR294","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fimmu.2017.00045","volume":"8","author":"A Ager","year":"2017","unstructured":"Ager A. High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function. Front Immunol. 2017;8:45.","journal-title":"Front Immunol"},{"key":"4292_CR295","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B. Targeting VEGF\/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978.","journal-title":"Front Immunol"},{"issue":"4","key":"4292_CR296","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","volume":"59","author":"BL Zhang","year":"2016","unstructured":"Zhang BL, et al. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci. 2016;59(4):340\u20138.","journal-title":"Sci China Life Sci"},{"issue":"5","key":"4292_CR297","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139.","journal-title":"Nat Med"},{"issue":"2","key":"4292_CR298","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang LC, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2(2):154\u201366.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"4292_CR299","doi-asserted-by":"publisher","first-page":"e1395997","DOI":"10.1080\/2162402X.2017.1395997","volume":"7","author":"EK Moon","year":"2018","unstructured":"Moon EK, et al. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology. 2018;7(3):e1395997.","journal-title":"Oncoimmunology"},{"issue":"4","key":"4292_CR300","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"4292_CR301","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res. 2017;5(12):1152\u201361.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4292_CR302","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","volume":"6","author":"A Nellan","year":"2018","unstructured":"Nellan A, et al. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018;6(1):30.","journal-title":"J Immunother Cancer"},{"key":"4292_CR303","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","volume":"393","author":"A Klampatsa","year":"2017","unstructured":"Klampatsa A, et al. Intracavitary \u2018T4 immunotherapy\u2019 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett. 2017;393:52\u20139.","journal-title":"Cancer Lett"},{"issue":"5","key":"4292_CR304","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"SC Katz","year":"2016","unstructured":"Katz SC, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016;23(5):142\u20138.","journal-title":"Cancer Gene Ther"},{"key":"4292_CR305","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, et al. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187.","journal-title":"J Immunol Res"},{"issue":"25","key":"4292_CR306","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai YT, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225\u201336.","journal-title":"Blood"},{"issue":"40","key":"4292_CR307","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","volume":"9","author":"DX Bu","year":"2018","unstructured":"Bu DX, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9(40):25764\u201380.","journal-title":"Oncotarget"},{"issue":"95","key":"4292_CR308","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.","journal-title":"Sci Transl Med"},{"issue":"5","key":"4292_CR309","doi-asserted-by":"publisher","first-page":"e0126007","DOI":"10.1371\/journal.pone.0126007","volume":"10","author":"M Schneider","year":"2015","unstructured":"Schneider M, et al. CD38 is expressed on inflammatory cells of the intestine and promotes intestinal inflammation. PLoS ONE. 2015;10(5):e0126007.","journal-title":"PLoS ONE"},{"issue":"1\u20132","key":"4292_CR310","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0006-8993(95)00885-T","volume":"697","author":"M Mizuguchi","year":"1995","unstructured":"Mizuguchi M, et al. Neuronal localization of CD38 antigen in the human brain. Brain Res. 1995;697(1\u20132):235\u201340.","journal-title":"Brain Res"},{"key":"4292_CR311","doi-asserted-by":"publisher","first-page":"6630295","DOI":"10.1155\/2021\/6630295","volume":"2021","author":"S Dwivedi","year":"2021","unstructured":"Dwivedi S, et al. CD38 and regulation of the immune response cells in cancer. J Oncol. 2021;2021:6630295.","journal-title":"J Oncol"},{"issue":"9","key":"4292_CR312","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/glycob\/cwy008","volume":"28","author":"C Steentoft","year":"2018","unstructured":"Steentoft C, et al. Glycan-directed CAR-T cells. Glycobiology. 2018;28(9):656\u201369.","journal-title":"Glycobiology"},{"key":"4292_CR313","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, et al. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139\u201352.","journal-title":"Annu Rev Med"},{"issue":"23","key":"4292_CR314","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez ER, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341\u201355.","journal-title":"Oncotarget"},{"issue":"38","key":"4292_CR315","doi-asserted-by":"publisher","first-page":"64607","DOI":"10.18632\/oncotarget.19929","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu X, et al. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017;8(38):64607\u201321.","journal-title":"Oncotarget"},{"issue":"4","key":"4292_CR316","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther"},{"issue":"1","key":"4292_CR317","doi-asserted-by":"publisher","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","volume":"7","author":"S Park","year":"2017","unstructured":"Park S, et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep. 2017;7(1):14366.","journal-title":"Sci Rep"},{"issue":"28","key":"4292_CR318","doi-asserted-by":"publisher","first-page":"19469","DOI":"10.18632\/oncotarget.24955","volume":"9","author":"D Valentini","year":"2018","unstructured":"Valentini D, et al. Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncotarget. 2018;9(28):19469\u201380.","journal-title":"Oncotarget"},{"issue":"7681","key":"4292_CR319","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran VP, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512\u20136.","journal-title":"Nature"},{"issue":"11","key":"4292_CR320","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"key":"4292_CR321","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fonc.2018.00081","volume":"8","author":"A Morrot","year":"2018","unstructured":"Morrot A, et al. Metabolic symbiosis and immunomodulation: how tumor cell-derived lactate may disturb innate and adaptive immune responses. Front Oncol. 2018;8:81.","journal-title":"Front Oncol"},{"key":"4292_CR322","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","volume":"11","author":"Y Yin","year":"2018","unstructured":"Yin Y, et al. Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics. 2018;11:20\u201338.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"4292_CR323","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382.","journal-title":"Cancer Cell"},{"issue":"508","key":"4292_CR324","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aax8861","volume":"11","author":"J Li","year":"2019","unstructured":"Li J, et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019;11(508):1.","journal-title":"Sci Transl Med"},{"issue":"6382","key":"4292_CR325","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"9","key":"4292_CR326","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"3","key":"4292_CR327","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"4292_CR328","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341.","journal-title":"Blood"},{"issue":"1","key":"4292_CR329","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"issue":"4","key":"4292_CR330","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569\u201381.","journal-title":"Immunity"},{"issue":"8","key":"4292_CR331","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"4292_CR332","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S267433","volume":"14","author":"L Ai","year":"2020","unstructured":"Ai L, et al. Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625\u201349.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4292_CR333","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"10","key":"4292_CR334","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4292_CR335","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol"},{"issue":"Spec Feature","key":"4292_CR336","first-page":"180","volume":"8","author":"LA Raedler","year":"2015","unstructured":"Raedler LA. Opdivo (nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8(Spec Feature):180\u20133.","journal-title":"Am Health Drug Benefits"},{"issue":"26","key":"4292_CR337","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"7528","key":"4292_CR338","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558\u201362.","journal-title":"Nature"},{"issue":"8","key":"4292_CR339","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"8","key":"4292_CR340","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","volume":"11","author":"L Wu","year":"2012","unstructured":"Wu L, et al. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther. 2012;11(8):1809\u201319.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4292_CR341","doi-asserted-by":"publisher","first-page":"e1440930","DOI":"10.1080\/2162402X.2018.1440930","volume":"7","author":"X Wu","year":"2018","unstructured":"Wu X, et al. Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. Oncoimmunology. 2018;7(7):e1440930.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4292_CR342","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.","journal-title":"Sci Rep"},{"issue":"4","key":"4292_CR343","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","volume":"11","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11(4):554\u201362.","journal-title":"Front Med"},{"key":"4292_CR344","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev-immunol-032712-095956","volume":"31","author":"NJ MacIver","year":"2013","unstructured":"MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013;31:259\u201383.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"4292_CR345","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"issue":"2","key":"4292_CR346","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390.","journal-title":"Immunity"},{"issue":"2","key":"4292_CR347","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4049\/jimmunol.1401710","volume":"196","author":"MA Ligtenberg","year":"2016","unstructured":"Ligtenberg MA, et al. Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J Immunol. 2016;196(2):759\u201366.","journal-title":"J Immunol"},{"key":"4292_CR348","doi-asserted-by":"publisher","first-page":"39833","DOI":"10.1038\/srep39833","volume":"7","author":"A Juillerat","year":"2017","unstructured":"Juillerat A, et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep. 2017;7:39833.","journal-title":"Sci Rep"},{"key":"4292_CR349","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357\u201362.","journal-title":"Comput Struct Biotechnol J"},{"issue":"9","key":"4292_CR350","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019;25(9):1341\u201355.","journal-title":"Nat Med"},{"issue":"4","key":"4292_CR351","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","volume":"18","author":"J Wei","year":"2021","unstructured":"Wei J, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021;18(4):792\u2013804.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"4292_CR352","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"10","key":"4292_CR353","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tig.2015.07.003","volume":"31","author":"A Saadatpour","year":"2015","unstructured":"Saadatpour A, et al. Single-cell analysis in cancer genomics. Trends Genet. 2015;31(10):576\u201386.","journal-title":"Trends Genet"},{"key":"4292_CR354","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3389\/fimmu.2018.01435","volume":"9","author":"DJ Kunz","year":"2018","unstructured":"Kunz DJ, Gomes T, James KR. Immune cell dynamics unfolded by single-cell technologies. Front Immunol. 2018;9:1435.","journal-title":"Front Immunol"},{"key":"4292_CR355","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.3389\/fimmu.2018.02582","volume":"9","author":"F Valdes-Mora","year":"2018","unstructured":"Valdes-Mora F, et al. Single-cell transcriptomics in cancer immunobiology: the future of precision oncology. Front Immunol. 2018;9:2582.","journal-title":"Front Immunol"},{"issue":"4","key":"4292_CR356","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccell.2020.03.008","volume":"37","author":"B Lim","year":"2020","unstructured":"Lim B, Lin Y, Navin N. Advancing cancer research and medicine with single-cell genomics. Cancer Cell. 2020;37(4):456\u201370.","journal-title":"Cancer Cell"},{"issue":"4","key":"4292_CR357","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nprot.2017.149","volume":"13","author":"V Svensson","year":"2018","unstructured":"Svensson V, Vento-Tormo R, Teichmann SA. Exponential scaling of single-cell RNA-seq in the past decade. Nat Protoc. 2018;13(4):599\u2013604.","journal-title":"Nat Protoc"},{"issue":"6359","key":"4292_CR358","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.aan6828","volume":"358","author":"MJT Stubbington","year":"2017","unstructured":"Stubbington MJT, et al. Single-cell transcriptomics to explore the immune system in health and disease. Science. 2017;358(6359):58\u201363.","journal-title":"Science"},{"issue":"1","key":"4292_CR359","doi-asserted-by":"publisher","first-page":"1866287","DOI":"10.1080\/2162402X.2020.1866287","volume":"10","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures. Oncoimmunology. 2021;10(1):1866287.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4292_CR360","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1038\/s41467-019-12464-3","volume":"10","author":"PA Szabo","year":"2019","unstructured":"Szabo PA, et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat Commun. 2019;10(1):4706.","journal-title":"Nat Commun"},{"issue":"2","key":"4292_CR361","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.gpb.2019.03.002","volume":"17","author":"I Xhangolli","year":"2019","unstructured":"Xhangolli I, et al. Single-cell analysis of CAR-T cell activation reveals a mixed T(H)1\/T(H)2 response independent of differentiation. Genomics Proteomics Bioinformatics. 2019;17(2):129\u201339.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"10","key":"4292_CR362","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1172\/JCI130059","volume":"130","author":"K Ishii","year":"2020","unstructured":"Ishii K, et al. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J Clin Invest. 2020;130(10):5425\u201343.","journal-title":"J Clin Invest"},{"issue":"4","key":"4292_CR363","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma X, et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol. 2020;38(4):448\u201359.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"4292_CR364","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.133977","volume":"5","author":"N Tang","year":"2020","unstructured":"Tang N, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4):1.","journal-title":"JCI Insight"},{"issue":"7764","key":"4292_CR365","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","volume":"571","author":"F Alfei","year":"2019","unstructured":"Alfei F, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019;571(7764):265\u20139.","journal-title":"Nature"},{"issue":"28","key":"4292_CR366","doi-asserted-by":"publisher","first-page":"14113","DOI":"10.1073\/pnas.1903520116","volume":"116","author":"RR Jadhav","year":"2019","unstructured":"Jadhav RR, et al. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc Natl Acad Sci USA. 2019;116(28):14113\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"4292_CR367","doi-asserted-by":"publisher","first-page":"e1005177","DOI":"10.1371\/journal.ppat.1005177","volume":"11","author":"PK Gupta","year":"2015","unstructured":"Gupta PK, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 2015;11(10):e1005177.","journal-title":"PLoS Pathog"},{"issue":"Supplement_1","key":"4292_CR368","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1182\/blood-2019-132273","volume":"134","author":"EF Moreno Cortes","year":"2019","unstructured":"Moreno Cortes EF, et al. Chimeric antigen receptor T cell therapy pipeline at a glance: a retrospective and systematic analysis from clinicaltrials.Gov. Blood. 2019;134(Supplement_1):5629\u20135629.","journal-title":"Blood"},{"issue":"1","key":"4292_CR369","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih A, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun. 2020;11(1):219.","journal-title":"Nat Commun"},{"issue":"1","key":"4292_CR370","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-017-0293-7","volume":"5","author":"Q Xue","year":"2017","unstructured":"Xue Q, et al. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. J Immunother Cancer. 2017;5(1):85.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4292_CR371","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"2","key":"4292_CR372","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ymthe.2020.11.028","volume":"29","author":"X Li","year":"2021","unstructured":"Li X, et al. Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell leukemia. Mol Ther. 2021;29(2):645\u201357.","journal-title":"Mol Ther"},{"issue":"4","key":"4292_CR373","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh N, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10(4):552\u201367.","journal-title":"Cancer Discov"},{"issue":"3","key":"4292_CR374","doi-asserted-by":"publisher","first-page":"e1009883","DOI":"10.1371\/journal.pcbi.1009883","volume":"18","author":"A Naghizadeh","year":"2022","unstructured":"Naghizadeh A, et al. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. PLoS Comput Biol. 2022;18(3):e1009883.","journal-title":"PLoS Comput Biol"},{"key":"4292_CR375","first-page":"eabq0225","volume":"2022","author":"KG Daniels","year":"2022","unstructured":"Daniels KG, et al. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science. 2022;2022:eabq0225.","journal-title":"Science"},{"key":"4292_CR376","doi-asserted-by":"publisher","first-page":"106084","DOI":"10.1016\/j.compbiomed.2022.106084","volume":"150","author":"R Zhang","year":"2022","unstructured":"Zhang R, et al. RCMNet: a deep learning model assists CAR-T therapy for leukemia. Comput Biol Med. 2022;150:106084.","journal-title":"Comput Biol Med"},{"issue":"3","key":"4292_CR377","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.celrep.2019.06.049","volume":"28","author":"FJ Hartmann","year":"2019","unstructured":"Hartmann FJ, et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy. Cell Rep. 2019;28(3):819-831.e4.","journal-title":"Cell Rep"},{"issue":"6434","key":"4292_CR378","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaw1219","volume":"363","author":"SG Rodriques","year":"2019","unstructured":"Rodriques SG, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363(6434):1463\u20137.","journal-title":"Science"},{"issue":"3","key":"4292_CR379","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259\u201375.","journal-title":"Ann Oncol"},{"issue":"11","key":"4292_CR380","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","volume":"7","author":"M Mata","year":"2017","unstructured":"Mata M, et al. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 2017;7(11):1306\u201319.","journal-title":"Cancer Discov"},{"issue":"2","key":"4292_CR381","doi-asserted-by":"publisher","first-page":"190035","DOI":"10.1001\/jamanetworkopen.2019.0035","volume":"2","author":"MD Whittington","year":"2019","unstructured":"Whittington MD, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs. chemotherapy for treatment of B-cell lymphoma. JAMA Netw Open. 2019;2(2):190035.","journal-title":"JAMA Netw Open"},{"issue":"19","key":"4292_CR382","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","volume":"318","author":"PB Bach","year":"2017","unstructured":"Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475,000 cancer drug. JAMA. 2017;318(19):1861\u20132.","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1186\/s12967-023-04404-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04292-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04292-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T10:28:42Z","timestamp":1700389722000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04292-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":382,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4292"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04292-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-023-04404-z","URL":"https:\/\/doi.org\/10.1186\/s12967-023-04404-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}